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We appreciate the author's feedback. We have discussed
their comments with our primary bariatric anesthesia group.
Based on their clinical experience, 30 years in one case,
they do not believe lidocaine to be very effective in
eliminating the fasciculations from succinylcholine (SUX),
and consequently postoperative myalgias. Rocuronium
(ROC), on the other hand, is effective in eliminating the
fasciculations, but it is painful on injection which is not
easily prevented by lidocaine. They still prefer using ROC
or other nondepolarizing agents for rapid sequence induc-
tions with complete success. The difference in onset
between SUX and ROC is 1–2 min which they consider
trivial compared to the time taken to accomplish the
intubation. Furthermore, if one prevents active vomiting
by excellent anesthesia and paralysis, and passive regurgi-
tation by “correct” cricoid pressure, then the amount of time
required for intubation is no longer critical. To quote them
directly: “The word ‘rapid’ in rapid sequence induction is
one of the worst words in the lexicon of anesthesia”. Their
preference is for “safe sequence inductions” so that time is
no longer relevant.
From a surgeon's standpoint, the additional side
effects of SUX (as outlined in our paper) are of equal
concern in this particular patient population. We agree
that one case may not define the entire practice. However,
when better drugs are available with a more favorable
overall profile, we also don't see the need to use SUX
instead of ROC.
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